Session Chair Profile

Ph.D., Head of Medical Diagnostics, US Medical Affairs Oncology, AstraZeneca

Dr. Omar Perez has over 17 years designing, deploying, and leading high-visibility oncology initiatives supporting global companion diagnostic developments, strategic partnerships and commercialization opportunities. Before joining AstraZeneca, he oversaw the global CDx developments for the GSK oncology portfolio, leading to diagnostic products for niraparib and dostarlimab. During his time at Pfizer, he led global CDx activities supporting the drug approvals of crizotinib, lorlatinib, dacomitinib talazoparib and inotuzomab. Notably, he led the first FDA approved NGS product for multiple targeted agents and helped establish the Center for Precision Medicine in LATAM to support Pfizer oncology products. Dr. Perez’s background includes roles in biotech and diagnostic companies, including co-founding Nodality, a diagnostic company focused on hematological malignancies. He is an inventor of the multiparametric phospho-proteomic flow technologies and an author of 37 publications and 35 patents.

 Session Abstract – PMWC 2022 Silicon Valley

Precision medicine is among the key contributors in progressing cancer survivorship. However, biomarker testing, which is critical to enabling precision medicine treatments, is below guideline recommendations due to various factors. The session will discuss these barriers, as well as bringing tangible and sustainable solutions to patients with cancer through collaboration.